Articles tagged with: Kennet Brysting

Grants awarded to 13 Canadian initiatives to help advance the goal of eliminating chronic Hepatitis C infection in high-risk populations

published: March, 22, 2018 Written by // Guest Authors - Revolving Door Categories // Social Media, Hep B and C, Current Affairs, Health, Revolving Door, Media, Guest Authors

Gilead Canada supports community leaders with local Hepatitis C micro-elimination efforts.

Grants awarded to 13 Canadian initiatives to help advance the goal of eliminating chronic Hepatitis C infection in high-risk populations

Mississauga, ON, March 14, 2018 – In support of Canada’s commitment to the World Health Organization’s (WHO) goal of eliminating chronic hepatitis C infection by 2030, Gilead Sciences Canada, Inc. (Gilead Canada) today announced a series of grants to support screening and linkage to care projects across Canada. These initiatives will focus on hepatitis C screening within high-risk patient populations and linking diagnosed patients to care. In total, 13 Hepatitis C Micro-Elimination Gran

Ontario expands patient access to chronic Hepatitis C therapies on public drug plan.

published: March, 06, 2018 Written by // Guest Authors - Revolving Door Categories // Social Media, Hep B and C, Current Affairs, Health, Revolving Door, Media, Guest Authors

Good news for those infected or co-infected with Hepatitis C in Ontario

Ontario expands patient access to chronic Hepatitis C therapies on public drug plan.

- Gilead applauds Ontario’s Ministry of Health for expanding access to curative hepatitis C therapies to all diagnosed patients, regardless of severity of illness - Ontario’s expanded access includes EPCLUSA®, a 12 week treatment for patients with chronic hepatitis C across all six genotypes - Gilead’s new product, VOSEVI™ is now available under the Ontario Drug Benefit Program - The removal of the fibrosis level criterion for access furthers Canada’s commitment to the World Heal

Multiple provinces and territories demonstrate leadership in the treatment of HIV/AIDS by providing access to GENVOYA®

published: May, 17, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Current Affairs, Treatment Guidelines -including when to start, General Health, Health, Revolving Door, Treatment, Guest Authors

Gilead's first TAF-based single tablet regimen demonstrates high efficacy with improved renal and bone parameters compared to TDF-based regimens.

Multiple provinces and territories demonstrate leadership in the treatment of HIV/AIDS by providing access to GENVOYA®

MISSISSAUGA, ON, May 4, 2017 /CNW/ - Gilead Sciences Canada, Inc. today announced that GENVOYA® tablets, for the treatment of HIV-1 infection, is now listed in multiple provinces and territories including, Ontario, Alberta, Quebec and Yukon, as well as in the Non-Insured Health Benefits (NIHB) Drug Plan for First Nations and Inuit. GENVOYA (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide) is indicated as a complete regimen for the treatment of h

Gilead receives approval in Canada for ODEFSEY™ for the treatment of HIV1 infection.

published: March, 07, 2017 Written by // Guest Authors - Revolving Door

Odefsey is the second single tablet regimen containing the Descovy™ backbone and the third product in Gilead’s new TAF portfolio to receive approval in Canada.

Gilead receives approval in Canada for ODEFSEY™ for the treatment of HIV1 infection.

Mississauga, On, February 16, 2017 – Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for ODEFSEY™ (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg) tablets as a complete regimen for the treatment of adults with HIV-1 infection. ODEFSEY is the most recent product approved from Gilead Canada’s range of tenofovir alafenamide (TAF)-based regimens that include GENVOYA® and DESCOVY™. ODEFSEY is indi